Systematic Reviews & Meta-analysis
M-A | Hydrocortisone shows no significant impact on 90-day mortality in septic shock patients
29 May, 2023 | 11:06h | UTCPatient-Level Meta-Analysis of Low-Dose Hydrocortisone in Adults with Septic Shock – NEJM Evidence
M-A | Effect of more vs. less intensive BP control on cardiovascular, renal and mortality outcomes in people with type 2 diabetes
29 May, 2023 | 10:37h | UTC
SR | Balanced crystalloid solutions versus 0.9% saline for treating acute diarrhea and severe dehydration in children
25 May, 2023 | 11:15h | UTC
M-A | Optimizing enteral nutrition delivery by implementing volume-based feeding protocol for critically ill patients
24 May, 2023 | 13:13h | UTC
SR | Videolaryngoscopy vs. direct laryngoscopy for tracheal intubation in neonates
24 May, 2023 | 13:11h | UTCVideolaryngoscopy versus direct laryngoscopy for tracheal intubation in neonates – Cochrane Library
Commentary on Twitter
Videolaryngoscopy:
– may increase the success of intubation on 1st attempt and result in fewer intubation attempts, but may not reduce the time required for successful intubation
– likely results in a reduced incidence of airway‐related adverse effectshttps://t.co/ney0pt8PnH pic.twitter.com/lc6bbDME7e— Cochrane Neonatal (@CochraneNeonate) May 12, 2023
SR | High-dose olanzapine in treatment-resistant schizophrenia
24 May, 2023 | 13:06h | UTC
SR | Management of lymph node–positive penile cancer
24 May, 2023 | 13:03h | UTCManagement of Lymph Node–positive Penile Cancer: A Systematic Review – European Urology
M-A | Risk and benefits of wakefulness-promoting drugs in obstructive sleep apnea patients
23 May, 2023 | 12:43h | UTCComparative Efficacy and Safety of Wakefulness-Promoting Agents for Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea: Systematic Review and Network Meta-analysis – Annals of Internal Medicine (link to abstract – $ for full-text)
News Release: Researchers find best treatment for excessive daytime sleepiness – McMaster University
M-A | Long-term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia
23 May, 2023 | 12:39h | UTC
M-A | Inhaled nitrous oxide for painful procedures in children and youth
22 May, 2023 | 13:29h | UTC
M-A | Evaluation of the effectiveness of telehealth chronic disease management system
16 May, 2023 | 14:55h | UTC
M-A | Is it necessary to wear compression stockings and how long should they be worn for preventing post thrombotic syndrome?
16 May, 2023 | 14:44h | UTC
M-A | Medial–lateral versus lateral-only pinning fixation in children with displaced supracondylar humeral fractures
16 May, 2023 | 14:32h | UTC
M-A | Postoperative clinical outcomes for kinematically, restricted kinematically, or mechanically aligned total knee arthroplasty
15 May, 2023 | 13:04h | UTC
M-A | Adding exercise to hypocaloric diet doesn’t enhance weight loss or glycemic control in T2D patients
15 May, 2023 | 12:52h | UTC
M-A | Effectiveness of diaphragmatic ultrasound as a predictor of successful weaning from mechanical ventilation
15 May, 2023 | 12:46h | UTC
M-A | First‐line therapy for adults with advanced renal cell carcinoma
12 May, 2023 | 13:33h | UTCSummary: Initial treatment for adults with advanced kidney cancer (renal cell carcinoma) – Cochrane Library
SR | Nasal high flow therapy for primary respiratory support in preterm infants
12 May, 2023 | 13:31h | UTCNasal high flow therapy for primary respiratory support in preterm infants – Cochrane Library
Summary: Nasal high flow therapy for breathing support in preterm babies – Cochrane Library
Commentary on Twitter
Nasal high flow therapy for primary respiratory support in preterm infants – 2023 updatehttps://t.co/6UEnZ8fJRS @AmerAcadPeds @ESPR_ESN pic.twitter.com/yLBcQPPPvS
— Cochrane Neonatal (@CochraneNeonate) May 6, 2023
M-A | Intensive blood pressure control for patients aged over 60
11 May, 2023 | 12:07h | UTC
SR | Perampanel add‐on for drug‐resistant focal epilepsy
11 May, 2023 | 11:55h | UTCPerampanel add‐on for drug‐resistant focal epilepsy – Cochrane Library
Summary: Perampanel add-on for drug-resistant focal epilepsy – Cochrane Library
Commentary on Twitter
💊 Perampanel add‐on for drug‐resistant focal #epilepsy
📚 Evidence from 7 trials involving 2,524 participants
"…effective @ reducing seizure frequency & may maintain seizure freedom…Perampanel is well‐tolerated at doses of 8 mg/day or less."https://t.co/LSJoYeDi8S— The Cochrane Library (@CochraneLibrary) April 17, 2023
M-A | Effects of different types of early rehabilitation on ventilator weaning among patients in the ICU
10 May, 2023 | 15:34h | UTC
SR | Educating health professionals in ultrasound guided peripheral intravenous cannulation
9 May, 2023 | 14:35h | UTC
M-A | Adverse events of cannabidiol use in patients with epilepsy
9 May, 2023 | 14:30h | UTC
M-A | Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer
9 May, 2023 | 14:24h | UTC
M-A | Quality of life after risk-reducing surgery for breast and ovarian cancer prevention
9 May, 2023 | 14:21h | UTC